At a Glance
| Detail | Antidote | Tessaract |
|---|---|---|
| Category | Practice Mgmt | Practice Mgmt |
| Total raised | $5M | $6.1M |
| Rounds tracked | 1 | 1 |
| Latest round | Seed, $5M · Jan 2026 | Series A, $6.1M · Oct 2025 |
| Last valuation | Not disclosed | Not disclosed |
| Lead investors | Lakestar | Mercia Ventures |
| Built for | Large firms | Not disclosed |
| Headquarters | United Kingdom | United Kingdom |
Funding, Side by Side
Antidote rounds
- Jan 2026Seed$5M
Tessaract rounds
- Oct 2025Series A$6.1M
Our Take
We have not tested these two head to head yet. The numbers above come from public funding announcements. If you use either one, tell us what you found and it may become a Field Note.
Quick Answers
- Which has raised more, Antidote or Tessaract?
- Tessaract has raised $6.1M in disclosed funding, compared with $5M for Antidote.
- Do Antidote and Tessaract share investors?
- No. None of the investors we track have backed both companies.
- What is Antidote best for?
- Antidote is AI billing compliance software that checks and corrects law firm time entries against client billing guidelines.
Source: Legal Tech Circle funding data, from public announcements. Updated November 10, 2026.